drugset / Trial / NCT05478473

Clinical Study of Chidamide Combined With Toripalimab in the Treatment of Advanced Melanoma

NCT05478473

NaSingle-groupOpen-labelTreatment

Summary

The study was a single-arm study designed to evaluate the efficacy and safety of Chidamide combined with Toripalimab.

Timeline

Start
2022-10-27
Primary completion
2023-08
Completion
2024-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Toripalimab Monoclonal antibody 240 mg Intravenous
Subject Tucidinostat Small molecule 30 mg Oral

Indications